Daxocox 100 mg Tablets for Dogs

Do not administer other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or
glucocorticoids concurrently or within 2 weeks of the last administration of this
veterinary medicinal product.

Special precautions for safe use in the target species:
Since the safety of the medicinal product has not been fully demonstrated in very
young animals, careful monitoring is advised during the treatment of young dogs
aged less than 6 months.
The active metabolite of enflicoxib exhibits an extended plasma half-life due to its low
rate of elimination. Use this veterinary medicinal product under strict veterinary
monitoring where there is a risk of gastrointestinal ulceration, or if the animal
previously displayed intolerance to NSAIDs.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
This veterinary medicinal product can cause hypersensitivity (allergic) reactions.
People with known hypersensitivity to NSAIDs should avoid contact with the
veterinary medicinal product.
Some NSAIDs may be harmful for the unborn child, especially during the third
trimester of pregnancy. Pregnant women should administer this veterinary medicinal
product with care.

Ingestion of this veterinary medicinal product may be harmful, especially for children,
and prolonged pharmacological effects leading to e.g. gastrointestinal disorders may
be observed. To avoid accidental ingestion, administer the tablet to the dog
immediately after removal from the blister packaging and do not split or crush tablets.
In case of accidental ingestion, seek medical advice immediately and show the
package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.